

Sulbactam/durlobactam: Adis Evaluation

Key Points

- A co-packaged product containing a β -lactam antibacterial and β -lactamase inhibitor (sulbactam) and a β -lactamase inhibitor (durlobactam) that has been being developed by Entasis Therapeutics Inc. for the treatment of infections caused by *Acinetobacter baumannii-calcoaceticus* complex (ABC)
- Received its first approval on 23 May 2023 in the USA
- Approved for use in patients 18 years of age and older for the treatment of HABP/VABP caused by susceptible isolates of ABC

Summary

Sulbactam/durlobactam (XACDURO®), is a co-packaged antibacterial product that has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by *Acinetobacter baumannii-calcoaceticus* complex (ABC).

Coadministration of durlobactam (a β -lactamase inhibitor with potent activity against a broad range of serine β -lactamases) with sulbactam (an established class A β -lactamase inhibitor with antibacterial activity against *A. baumannii*) prevents sulbactam degradation by ABC-produced β -lactamases.

In May 2023, sulbactam/durlobactam was approved in the USA for use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of ABC.

This summary represents the opinions of the [author/authors]. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. © Springer Nature Switzerland AG 2023.